NASDAQ · Biotechnology · USD

Pulmatrix, Inc. (PULM) Stock Analysis

Pulmatrix, Inc. (PULM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PULM

$1.39

+$0.03 (+2.21%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PULM with… →

PULM Key Statistics

As of Sep 4, 2026

Trading

Open: $1.36
Previous Close: $1.36
Day's Range: 1.36–1.45
52-Week Range: 1.16–5.50
Volume: 20.20K
Beta: 1.90

Valuation

Market Cap: $5.08M
P/E Ratio: unprofitable
EPS (ttm): −1.10

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$5.16M
Profit margin: 0.00%
Shares Outstanding: 3.65M
1-Year Return: −70.98%

Dividend and dates

Avg Volume: 46.99K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PULM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−82.98%+275.27%−37.67%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−37.67%
2025	−68.05%
2024	+275.27%
2023	−52.06%
2022	−55.71%
2021	−63.19%
2020	+38.37%
2019	−64.17%
2018	−82.98%
2017	+138.98%
2016 (partial year)	−69.90%

As of September 4, 2026.

PULM Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$5.16M	—
2024	$7.81M	−$9.56M	−122.5%
2023	$7.30M	−$14.12M	−193.5%
2022	$6.07M	−$18.84M	−310.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$5.17M	−$5.16M	—
2024	$7.81M	—	−$7.15M	−$9.56M	−122.5%
2023	$7.30M	—	−$14.74M	−$14.12M	−193.5%
2022	$6.07M	—	−$18.95M	−$18.84M	−310.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PULM Valuation vs Biotechnology Median

Median of 656 stocks

Metric	PULM	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Pulmatrix, Inc. (PULM) is capitalised at $5.08M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 2 employees.

The 52-week range on file runs from $1.16 to $5.50. The most recent close on file for PULM is $1.39, dated September 4, 2026. That is +$0.03 (+2.21%) against the previous close. The latest close sits 19.83% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. That is −100.00% against the prior fiscal year, when revenue was $7.81M. The same year closed with a net loss of $5.16M. The reported profit margin is 0%. Trailing earnings per share are −1.1.

Across the 4 fiscal years on file, revenue moves from $6.07M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is −70.98%. Across 10 years the annualized return works out at −42.13%. The reported beta is 1.9. Annualized volatility over the trailing 10 years is 111.22%.

Growth & Income

The record shows no dividend for PULM.

So far in 2026 the price is −37.67%. Across the complete calendar years on file, 2024 returned +275.27% and 2018 returned −82.98%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Pulmatrix, Inc. (PULM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Pulmatrix, Inc.	PULM	$5.08M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Pulmatrix, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Pulmatrix, Inc.

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Visit website →